Research recommendation(s) from an individual piece of guidance
|Guidance:||Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban|
|Date issued:||July 2012|
Research recommendations coming out of this guidance
- Further research on the clinical effectiveness of rivaroxaban compared with low molecular weight heparin (LMWH) in patients with active cancer should be conducted.
This page was last updated: 14 November 2013